Tumor-specific CD8+ T cells were shown to more frequently infiltrate the TME; highly express a myriad of activation markers, including IFNg, CD44, CD69, and CXCR3; and were more efficient at directly killing cancer cells when treated with radiation + PD1-IL2v. The gene discussed is CD8A; the disease is cancer.